Ue Lifesciences (India) Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 2.86 M
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 239.89%
- Profit Growth -4.01%
- Ebitda -0.41%
- Net Worth 38.06%
- Total Assets 204.41%
About Ue Lifesciences (India)
Ue Lifesciences (India) Private Limited (ULIPL) is a registered startup operating as a Private Limited Foreign Company Incorporated In India incorporated in India on 28 September 2015 (Nine years and four months 25 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.86 M, as per Ministry of Corporate Affairs (MCA) records.
Bhaumik Sanghvi, Mihir Shah, Gaurang Shah, and One other member serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74900MH2015FTC268726
- Company No.
268726
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
28 Sep 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Ue Lifesciences (India)?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhaumik Sanghvi  | Director | 28-Sep-2015 | Current |
| Mihir Shah | Director | 28-Sep-2015 | Current |
| Gaurang Shah | Director | 29-Jul-2023 | Current |
| Chandan Navalkar | Director | 30-Sep-2022 | Current |
Financial Performance of Ue Lifesciences (India).
Ue Lifesciences (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 239.89% increase. The company also saw a slight decrease in profitability, with a 4.01% decrease in profit. The company's net worth Soared by an impressive increase of 38.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ue Lifesciences (India)?
In 2023, Ue Lifesciences (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Lanatomie Private LimitedChandan Navalkar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ue Lifesciences (India)?
Ue Lifesciences (India) has a workforce of 42 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ue Lifesciences (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ue Lifesciences (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
